Highly experienced medicinal chemist joins to further strengthen Amphista’s next generation TPD approach
Cambridge, UK, June 26, 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announced that Giles Brown, PhD, has been appointed as Senior Vice President (SVP) of Chemistry with immediate effect.
In this role, Giles will work with the leadership team and scientists to advance the Company’s drug discovery pipeline and deliver therapeutic candidates.
He brings over 20 years’ experience in medicinal chemistry during which he contributed to the discovery and development of fifteen preclinical candidates, of which seven successfully entered clinical trials. He joins Amphista from Dunad Therapeutics where he served as Senior Vice President of Chemistry focusing on the discovery of molecular glues. Prior to this, Giles held senior roles at OMass Therapeutics and Sosei Heptares. He holds a PhD from the University of Bristol and his MBA from Henley Business School, UK.
Nicola Thompson, Chief Executive Officer of Amphista Therapeutics said: “Giles is an exceptional chemist and leader with an outstanding track record of drug discovery. His appointment to Amphista reflects the strength of the innovative approach we are taking in TPD to deliver a new generation of therapeutic molecules. We very much look forward to working with Giles to further advance our technology and drug discovery pipeline.”
Giles Brown, Senior Vice President of Chemistry of Amphista Therapeutics, added: “Amphista’s differentiated, next-generation, approach to targeted protein degradation, and its proprietary platform technology, offer a unique opportunity for the discovery of novel, differentiated medicines. I am excited to be joining a team of innovators to advance the Company’s chemistry-led strategy and progress the pipeline to deliver potential medicines for many hard-to-treat diseases.”
About Amphista Therapeutics
Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD). They aim to address the challenges faced by earlier stage TPD research and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s laboratories at the University of Dundee. The Company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, Eli Lilly & Company and The Dementia Discovery Fund. For more information, please visit: www.amphista.com
For more information please contact:
Nicki Thompson, CEO
Consilium Strategic Communications
Amber Fennell, Namrata Taak, Stella Lempidaki
Tel: +44 (0)20 3709 5813